Document Detail


Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis.
MedLine Citation:
PMID:  12004254     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To review the physiologic and biochemical mechanisms and the rationale for the use of soluble thrombomodulin, plasma-derived protein C, and recombinant human activated protein C in sepsis. DATA SOURCES AND STUDY SELECTION: Research and review articles related to the protein C pathway published in English from 1960 to present. DATA EXTRACTION AND SYNTHESIS: The protein C anticoagulant pathway plays a major role in controlling microvascular coagulation and inflammation. Protein C is the zymogen of the vitamin K-dependent serine protease activated protein C. Protein C is converted to activated protein C when thrombin complexes with thrombomodulin, an endothelial surface transmembrane glycoprotein. Activated protein C inactivates factors Va and VIIIa and effectively limits further thrombin generation. This protein also enhances endogenous fibrinolytic activity and modulates the inflammatory response. A rapid depletion of protein C occurs in sepsis, which contributes to sepsis-induced coagulopathy and correlates with a poor prognosis. The decrease in tissue levels of thrombomodulin in patients with meningococcemia suggests that the ability to convert protein C to activated protein C may also be compromised. The ability of soluble thrombomodulin to block fibrinogen clotting and cell activation, to activate protein C, and to promote thrombin inhibition in different animal models suggests that soluble thrombomodulin could be a useful therapeutic agent in sepsis. However, soluble thrombomodulin is less effective in blocking fibrinogen and platelet activation and in promoting thrombin inhibition than endothelial surface membrane-bound thrombomodulin. Only activated protein C, and not protein C, has clearly shown a reduction in mortality in experimental animal models of sepsis and in humans. CONCLUSIONS: The multipotent pharmacodynamic effects (antithrombotic, profibrinolytic, and anti-inflammatory) of activated protein C may explain why recombinantly derived human activated protein C is the first experimental agent to demonstrate a significant survival benefit in patients with severe sepsis.
Authors:
Jean-François Dhainaut; S Betty Yan; Alain Cariou; Jean-Paul Mira
Related Documents :
2851994 - Interference of blood-coagulation vitamin k-dependent proteins in the activation of hum...
23925114 - Paar-repeat proteins sharpen and diversify the type vi secretion system spike.
24735874 - Ovol proteins: guardians against emt during epithelial differentiation.
24721674 - Site-specific characterization of cell membrane n-glycosylation with integrated hydroph...
16544054 - Genetic algorithms as a tool for helix design--computational and experimental studies o...
10450164 - Identification of bacterial proteins observed in maldi tof mass spectra from whole cells.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Critical care medicine     Volume:  30     ISSN:  0090-3493     ISO Abbreviation:  Crit. Care Med.     Publication Date:  2002 May 
Date Detail:
Created Date:  2002-05-10     Completed Date:  2002-05-24     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0355501     Medline TA:  Crit Care Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S318-24     Citation Subset:  AIM; IM    
Affiliation:
Medical Intensive Care Unit, Cochin St. V. de Paul Hospital, AP-HP, Cochin Institut-Cochin Port-Royal Medical School, University of Paris V, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Disseminated Intravascular Coagulation / metabolism,  physiopathology*
Fibrinolytic Agents / therapeutic use*
Humans
Protein C / metabolism,  physiology*,  therapeutic use*
Recombinant Proteins / therapeutic use*
Sepsis* / drug therapy,  metabolism,  physiopathology
Thrombomodulin / metabolism,  physiology*
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Protein C; 0/Recombinant Proteins; 0/Thrombomodulin; 0/drotrecogin alfa activated
Comments/Corrections
Comment In:
Crit Care Med. 2003 May;31(5):1597   [PMID:  12771650 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Platelet function in sepsis.
Next Document:  Antithrombin, heparin, and heparan sulfate.